Antibody Engineering for Immune Checkpoint Blockade

While immune checkpoint blockade has revolutionized the treatment of multiple cancers, only a subset of patients initially respond and many relapse with acquired resistance to this treatment. Using a combination of modeling and antibody engineering strategies, this project aims to explore the mechanisms of the PD-1/PD-L1 checkpoint axis to improve the therapeutic efficacy when drugging these targets.